Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase

Figure 5

Cyproheptadine induces p38 MAPK activation in HepG2 cells and activation of p38 MAPK and CHK2 in Huh-7 cells. Western blot analysis was performed to detect p38, CHK2, p53, and their phosphorylated forms in HCC cells following treatment with 40 μM cyproheptadine for different lengths of time. The level of Thr180/Tyr182-phosphorylated p38 MAPK markedly increased in both HCC cell lines after 1 h of treatment, indicating p38 MAPK activation. The level of Thr68-phosphorylated CHK2 increased independently of the level of Ser20-phosphorylated p53 in Huh-7 cells (but not in HepG2 cells) after treatment, indicating CHK2’s p53-independent role in cell cycle arrest in this cell line.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us